Organization
Barts Cancer Centre
2 abstracts
Abstract
Clinical validation of image-based AI predictive biomarkers for precision neoadjuvant triple-negative breast cancer treatment (PEAR-TNBC).Org: Ourotech Ltd t/a Pear Bio, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Manchester University Foundation Trust, Barts Cancer Centre,
Abstract
Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors.Org: Barts Cancer Institute, Barts Cancer Centre, Queen Mary University of London, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, St Bart's Hospital,